Hybio Pharmaceutical Co., Ltd. (SHE:300199)

Hybio Pharmaceutical Revenue

Hybio Pharmaceutical had revenue of 554.08M CNY in the quarter ending September 30, 2026, with 314.48% growth. This brings the company's total for the last twelve months to 1.53B, up 69.87% year-over-year. In the year 2025, Hybio Pharmaceutical had annual revenue of 966.35M with 63.73% growth. That makes Hybio Pharmaceutical the 16,489th largest company in the world by revenue and 2,997th in China.

• Revenue (ttm): 1.53B
• Revenue Growth: +69.87%
• P/S Ratio: 12.66
• Revenue / Employee: 1.24M
• Employees: 1,226
• Market Cap: 19.31B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• Foreign 598.42M 61.9%
• China 367.93M 38.1%

Fiscal year ended Dec 31, 2025 See the full Hybio Pharmaceutical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	966.35M	376.15M	63.73%
Dec 31, 2024	590.20M	158.81M	36.82%
Dec 31, 2023	431.38M	-272.94M	-38.75%
Jan 1, 2023	704.32M	-31.65M	-4.30%
Jan 1, 2022	735.97M	14.25M	1.97%

Data Source: S&P Global Market Intelligence Last updated: Oct 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error